JHP Pharmaceuticals Enters Manufacturing Pact

JHP Pharmaceuticals has entered into a multi‐year contract manufacturing agreement with an undisclosed biotechnology company. JHP will be responsible for the manufacture and supply of an approved therapy used to treat cancer.

Stuart Hinchen, president and co‐founder of JHP, said, “We recognize that being selected to produce this crucial drug demonstrates our ability to meet critical marketplace needs. JHP was able to achieve the rigorous timelines required to manufacture this drug through a quality‐driven, experienced staff and a customer‐centric approach. Additionally, our record of cGMP compliance, coupled with our experience in manufacturing site transfers, put us in the position to serve this important customer.”

Mr. Hinchen also noted, “This will be the second multi‐year contract JHP has entered during the last two months. These agreements are examples of how our approach to ongoing investment in our people and facilities allow us to focus on customer needs which results in rising, sustainable growth. Our Rochester, MI manufacturing site has a solid history of successful partnerships, manufacturing both clinical and commercial products.”


Click here to learn more about JHP Pharmaceuticals